Screener
ImmunityBio, Inc. IBRX Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Classification | March 31, 2026 | December 31, 2025 |
|---|---|---|---|
| Liabilities | |||
| Current: | |||
| Operating lease liabilities (including amounts with related parties) | Operating lease liabilities | $7,626 | $7,535 |
| Finance lease liabilities | Accrued expenses and other liabilities | 53 | 52 |
| Noncurrent: | |||
| Operating lease liabilities (including amounts with related parties) | Operating lease liabilities, less current portion | 33,147 | 33,447 |
| Finance lease liabilities | Other liabilities | 213 | 227 |
| Total lease liabilities (including amounts with related parties) | $41,039 | $41,261 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s current debt?
- ImmunityBio, Inc. (IBRX) reported current debt of $53K in Q1 2026.
- What does current debt mean?
- The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.
Ask your AI about ImmunityBio, Inc.'s current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude